To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Registration Number
- NCT00946465
- Lead Sponsor
- Sandoz
- Brief Summary
To demonstrate the relative bioavailability study of Ramipril 10 mg capsules under fasting conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 Ramipril 10 Capsule (Sandoz) Ramipril 10 Capsule (Sandoz) 2 Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical) Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
- Primary Outcome Measures
Name Time Method Bioequivalence based on AUC and Cmax 30 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of ramipril in ACE inhibition for hypertension management?
How does the bioavailability of Sandoz ramipril 10 mg compare to Aventis Altace in fasting conditions?
Are there specific biomarkers that correlate with improved outcomes in ACE inhibitor therapy for resistant hypertension?
What are the adverse event profiles of ramipril formulations in phase 1 trials for cardiovascular patients?
How do angiotensin-converting enzyme inhibitors like ramipril compare to ARBs in first-line hypertension treatment guidelines?